Searched for
CIPLA OUTLOOK
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Geopolitical stability will decide market’s next move: Sandip SabharwalIndian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...
- Strong revenue growth fails to shield India Inc margins in March quarterCorporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...
- Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...
- Is India Inc's CSR truly driving systemic change or just shifting funds?Corporate India is entering a new phase of CSR. Spending is expected to cross ₹1.2 lakh crore by 2035. Companies are shifting towards syste...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked targetCipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...
- Q4 earnings, crude oil, FII action among 8 factors to steer D-Street this weekIndian stock markets are set for a busy week. Key events like Q4 earnings announcements for many companies will influence trading. Foreign ...
- Most hated stocks: FIIs dumping these 146 companies without a break for 4 straight quarters. Do you own any?Foreign institutional investors have been consistently selling shares in 146 Indian companies for four consecutive quarters. This selling s...
- Pharma stocks buck market weakness as Dr Reddy's gainsPharma stocks showed strength on Thursday, defying market weakness. Dr Reddy's Laboratories saw significant gains, fueled by anticipation o...
- Cipla promoters sell 2.53% stake for around Rs 2,600 crorePromoters of Cipla, including Person Acting in Concert, sold 2.04 crore shares in a block deal worth around Rs 2,600 crore to create liquid...
- Promoter group entities likely to sell 2.5% stake in Cipla worth Rs 2,637 crore via block deals: ReportThe price range of the block is fixed at Rs 1,289-1,357, taking the total deal value to around Rs 2,637 crore.
- Cipla shares surge over 6% post Q4 results. Should you buy or sell?Meanwhile, EBITDA for the quarter under review increased 13% YoY to Rs 1,316 crore as against 1166 crore in the last year period.
- Buy Cipla, target price Rs 1,090: ICICI DirectICICI Direct has issued a buy call on Cipla with a target price of Rs 1090, higher than the current market price of Rs 914.45. Analysts pro...
- Dispute settlement gives this stock an edge over peers in pharma packKunal Dhamesha of Emkay Global raised his price target for the stock to Rs 1,000 and sees potential gain of Rs 45 per share from the settle...
- Analysts give a thumbs up to Cipla’s Q2 report card, see 30% upside in the stockJefferies was the most optimistic as it maintained its buy rating on the stock, and raised the target price to Rs 1,024 from Rs 914 earlier.
- HSBC downgrades Cipla to 'hold', target price Rs 450The stock ended down 0.2% at Rs 421.45 on Thursday.
- Buy Aurobindo Pharma for Rs 1450-1500 target in 3 weeks: Devang VisariaWith a three weeks' time horizon, we are looking for targets closer to Rs 1,450-1,500 for Aurobindo Pharma.
- If Cipla continues to go down, it may not be defensive in near future: Deepak MohoniDeepak Mohoni, Director, trendwatchindia.com in a chat with ET Now gives his outlook on Cipla.
Load More
